Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

• Status: Completed
• Trial end date: 2014-11-01

Summary

Primary Objective:

• To assess the tolerability at global doses

Secondary Objectives:

• Safety

• Pharmacokinetics

• Efficacy

• Phase: Phase 1

Details

• Lead Sponsor: Sanofi
• Treatments: Hormones; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate